Grufity logoGrufity logo
Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
LRMR

LRMR - Larimar Therapeutics, Inc. Stock Price, Fair Value and News

$6.16+0.03 (+0.49%)
Market Closed
Max Portfolio Pct.
Check
Valuation
Check

Stock Quality:

GPSDBMFI
Max Portfolio Pct.
Check
Valuation
Check
GPSDBMFI

LRMR Price Action

Last 7 days

-7.9%

Last 30 days

-16.2%

Last 90 days

-21.6%

Trailing 12 Months

85.5%

LRMR RSI Chart

LRMR Valuation

Market Cap

393.0M

Price/Earnings (Trailing)

-6.07

Price/Sales (Trailing)

225.75

Price/Free Cashflow

-8.74

LRMR Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

LRMR Fundamentals

LRMR Revenue

Revenue (TTM)

2.3M

LRMR Earnings

Earnings (TTM)

-64.8M

Earnings Growth (Yr)

-71%

Earnings Growth (Qtr)

28.33%

LRMR Profitability

Return on Equity

-32.65%

Return on Assets

-29.57%

Free Cashflow Yield

-11.44%

LRMR Investor Care

Shares Dilution (1Y)

45.33%

Diluted EPS (TTM)

-1.14

LRMR Alerts

  • JANUS HENDERSON GROUP PLC reported owning 8.7% of LRMR [2024-11-14]
  • GOLDMAN SACHS GROUP INC reported owning 7% of LRMR [2024-11-06]

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20192.3M000
20181.0M1.1M1.5M1.9M
2017912.0K934.0K970.0K996.0K
2016608.0K770.0K857.0K894.0K
2015130.5K233.0K335.5K438.0K
201400028.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About Larimar Therapeutics, Inc.

LRMR
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is headquartered in Bala Cynwyd, Pennsylvania.
 CEO
 WEBSITElarimartx.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES26

Larimar Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Larimar Therapeutics, Inc.? What does LRMR stand for in stocks?

LRMR is the stock ticker symbol of Larimar Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Larimar Therapeutics, Inc. (LRMR)?

As of Fri Nov 22 2024, market cap of Larimar Therapeutics, Inc. is 393.05 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of LRMR stock?

You can check LRMR's fair value in chart for subscribers.

Is Larimar Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether LRMR is over valued or under valued. Whether Larimar Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Larimar Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LRMR.

What is Larimar Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Nov 22 2024, LRMR's PE ratio (Price to Earnings) is -6.07 and Price to Sales (PS) ratio is 225.75. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LRMR PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Larimar Therapeutics, Inc.'s stock?

In the past 10 years, Larimar Therapeutics, Inc. has provided -0.122 (multiply by 100 for percentage) rate of return.